Recombinant Human IFN-gamma R1/CD119 His-tag Protein, CF

Recombinant Human IFN‑ gamma R1/CD119 His-tag Protein (Catalog # 11030-IR) has a molecular weight (MW) of 34.5 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (e.g. Glycosylation).

2 μg/lane of Recombinant Human IFN-gamma R1/CD119 His-tag Protein (Catalog # 11030-IR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 36-46 kDa.

When Recombinant Human IFN-gamma (HEK293-expressed) Protein (10067-IF) is immobilized at 3 µg/mL (100 µL/well), Recombinant Human IFN-gamma R1/CD119 His-tag Protein (Catalog # 11030-IR) binds with an ED50 of 0.0750-0.900 µg/mL.

• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IFN-gamma R1/CD119 His-tag Protein, CF Summary

• Additional Information: Analyzed by SEC-MALS
• Details of Functionality: Measured by its binding ability in a functional ELISA.

  When Recombinant Human IFN-gamma (HEK293-expressed) (Catalog # 10067-IF) is immobilized at 3 µg/mL (100 µL/well), Recombinant Human IFN-gamma R1/CD119 His-tag (Catalog # 11030-IR) binds with an ED₅₀ of 0.0750-0.900 µg/mL.

• Source: Human embryonic kidney cell, HEK293-derived human IFN-gamma R1/CD119 protein
  Glu18-Gly245, with a C-terminal 6-His tag
• Accession #: P15260.1
• N-terminal Sequence: Glu18
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 27 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 36-46 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 400 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IFN-gamma R1/CD119 His-tag Protein, CF

• AVP, type 2
• CD119 antigen
• CD119
• FLJ45734
• IFN-gamma R1
• IFN-gamma receptor 1
• IFNgammaR1
• IFN-gamma-R1
• IFNGR
• IFNGR1
• IFN-gR1
• immune interferon receptor 1
• interferon gamma receptor 1
• interferon-gamma receptor alpha chain
• type 2

Background

Interferon gamma receptor 1 (IFNGR1), along with IFNGR2, are type II cytokine receptors that combine to form a high affinity signaling complex with the type II interferon, IFNG. Mature human IFNGR1 consists of an extracellular domain (ECD) with 2 Ig-like domains, a transmembrane domain and an intracellular domain with both Jak1 and Stat1 binding motifs. The ECD of human IFNGR1 shares 50% amino acid sequence identity with mouse IFNGR1. The IFNG signaling complex is formed by 2 IFNGR1 subunits binding one IFNG dimer directly, and then 2 IFNGR2 molecules further stabilizing the receptor complex. Complex formation then triggers a signaling cascade that culminates in the transcription of the interferon stimulated genes (ISGs) and additional transcription factors. Ultimately, IFNGR1 mediated signaling regulates several biological processes including innate and acquired immune response, apoptosis and cell cycle progression. IFNGR1 is constitutively expressed in most cell types and deletions or mutations to IFNGR1 result in reduced resistance to bacterial, parasitic, and viral infection.

1. Bhat, M.Y. et al. (2018) J. Cell Commun Signal 12:745.
2. de Weerd, N.A. and Nguyen, T. (2012) Immunol Cell Biol. 90:483.
3. Mendoza, J.L. et al. (2019) Nature 567:56.
4. Blouin, C.M. and Lamaze, C. (2013) Front Immunol. 4:267.
5. Alspach, E. et al. (2019) Cold Spring Harb Perspect Biol. 11:a028480.

Bioinformatics

• Uniprot:
  • P15260.1()